Evidence map›Paper›PMID 22636422›Full record

ArticleJournal of lipid research2012

High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli.

Loren E Smith, Jun Yang, Leah Goodman, Xinqi Huang, Rong Huang, James Dressman, Jamie Morris, R A Gangani D Silva, W Sean Davidson, Giorgio Cavigiolio

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Purification of bacteriophage lambda repressor.Protein expression and purification · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Loren E SmithDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45273, USA.
Jun Yang
Leah Goodman
Xinqi Huang
Rong Huang
James Dressman
Jamie Morris
R A Gangani D Silva
W Sean Davidson
Giorgio Cavigiolio
University of Cincinnati · US

Funding

Apolipoprotein A-I structure in high density lipoproteinsR01HL067093 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 2002 to 2016
$4.3M
APOLIPOPROTEIN-MEDIATED CHOLESTEROL EFFLUXR01HL062542 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 1999 to 2008
$2.2M
Impact of self-association on structure and function of apolipoprotein A-IR01HL113059 · NHLBI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI CAVIGIOLIO, GIORGIO · 2012 to 2016
$2.0M
The roles of apolipoprotein A-IV structure and lipid affinity in its functionR01HL082734 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 2006 to 2009
$1.2M
The role of apolipoprotein A-II in the modulation of HDL functionR00HL087561 · NHLBI · UNIVERSITY OF CINCINNATI · PI SILVA, RANASINGHE · 2009 to 2011
$742k
The Role of Apolipoprotein A-II in the Modulation of HDL FunctionK99HL087561 · NHLBI · UNIVERSITY OF CINCINNATI · PI SILVA, RANASINGHE · 2007 to 2008
$174k
NHLBI NIH HHS HL082734NHLBI NIH HHS HL113059NHLBI NIH HHS HL62542NHLBI NIH HHS HL67093NHLBI NIH HHS K99 HL087561NHLBI NIH HHS K99/R00 HL087561NHLBI NIH HHS R00 HL087561NHLBI NIH HHS R01 HL062542NHLBI NIH HHS R01 HL067093NHLBI NIH HHS R01 HL082734NHLBI NIH HHS R01 HL113059
6 · The paper itself

Abstract

Recombinant expression systems have become powerful tools for understanding the structure and function of proteins, including the apolipoproteins that comprise human HDL. However, human apolipoprotein (apo)A-II has proven difficult to produce by recombinant techniques, likely contributing to our lack of knowledge about its structure, specific biological function, and role in cardiovascular disease. Here we present a novel Escherichia coli-based recombinant expression system that produces highly pure mature human apoA-II at substantial yields. A Mxe GyrA intein containing a chitin binding domain was fused at the C terminus of apoA-II. A 6× histidine-tag was also added at the fusion protein's C terminus. After rapid purification on a chitin column, intein auto-cleavage was induced under reducing conditions, releasing a peptide with only one extra N-terminal Met compared with the sequence of human mature apoA-II. A pass through a nickel chelating column removed any histidine-tagged residual fusion protein, leaving highly pure apoA-II. A variety of electrophoretic, mass spectrometric, and spectrophotometric analyses demonstrated that the recombinant form is comparable in structure to human plasma apoA-II. Similarly, recombinant apoA-II is comparable to the plasma form in its ability to bind and reorganize lipid and promote cholesterol efflux from macrophages via the ATP binding cassette transporter A1. This system is ideal for producing large quantities of recombinant wild-type or mutant apoA-II for structural or functional studies.

Indexed as

Amino Acid SequenceApolipoprotein A-IICircular DichroismCulture TechniquesEscherichia coliGene ExpressionGenetic EngineeringHumansMass SpectrometryMolecular Sequence DataRecombinant Fusion ProteinsApolipoprotein A-IIRecombinant Fusion Proteins

Identifiers

PMID22636422
PMCPMC3540857
OpenAlexW2148728668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.